Vivus (VVUS)
News
| May 31 | @epime7heus $arna $vvus .. Logical thing to do, Fda needs to give doctors and patients a choice. So i think they will both get approved by LionShare |
| May 31 | @epime7heus $VVUS and why was it delayed? by Bleedblue |
| May 31 | @Bleedblue $VVUS has other drugs, all $ARNA eggs are in weight loss basket and has all the same safety concerns and problems $VVUS does by epime7heus |
| May 31 | $VVUS has problems, $ARNA does not. panel vote means nothing and were only talking 2 votes dif. by Bleedblue |
| May 31 | @Bleedblue $VVUS is standing in $ARNA's way with a more unanimous panel vote then ARNA got so VVUS is more likely to get approved if only 1 by epime7heus |
| May 31 | @SomeGuy900 JMO from facts and analysis,no secrets. MO is also $VVUS will not be approved for some time. ARNA will already be in motion. by svtechie |
| May 31 | @low_level_owl $ARNA The initial draft of the $VVUS REMS was submitted on Dec. 28, 2009; it was likely discussed for 6 to 12 months earlier by SlownSteady |
| May 31 | @slownsteady...$ARNA much smarter in marketing and distribution than $VVUS. We have it they dont...sux for $VVUS by svtechie |
| May 31 | Invest in the Market's Hottest Sector Fool |
| May 31 | RT @SlownSteady @Njodogg $ARNA The $VVUS announcement came after regular trading hours.>An example of how the "man" screws the retailer by RickPalmer907 |
| May 31 | Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge? Benzinga |
| May 30 | Keep a Close Eye on VIVUS Fool |
| May 30 | Traders Eying Arena (ARNA) Closely ahead of June PDUFA Street Insider |
| May 30 | Trade adjusts bullish position in Vivus |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
Vivus is a small pharmaceutical company working in obesity, sleep, and sexual health. Vivus is developing an erectile dysfunction drug, Avanafil, that is in Phase 3 clinical trials. A documentary movie "Orgasm Inc." was made at Vivus in 2009 to document the process of creating a treatment for Female sexual arousal disorder. VIVUS, Inc. has a licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Avanafil. The company was founded by Virgil A Place on April 16, 1991 and is headquartered in Mountain View, California.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Vivus is up 173.7% over the last year vs S&P 500 Total Return down 0.41%, Arena Pharmaceuticals up 350.3%, and Orexigen Therapeutics down 5.42%.
- VVUS Total Returns
- ^SPXTR Total Returns
- ARNA Total Returns
- OREX Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these VVUS related companies
Pro Strategies Featuring VVUS
Did Vivus make it into our Pro Portfolio Strategies?
VVUS Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other VVUS Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VVUS | 23.70 | -1.09 | -4.40% | 2.429B |
| VVTV | 1.69 | -0.05 | -2.87% | 84.48M |
| VVR | 4.65 | +0.02 | +0.43% | |
| VVI | 17.37 | -0.34 | -1.92% | 356.86M |
| VVC | 28.68 | -0.64 | -2.18% | 2.404B |
| VV | 58.84 | -1.26 | -2.10% | |
| VUG | 64.75 | -1.56 | -2.35% | |
| VTV | 52.71 | -1.06 | -1.97% | |
| VTUS | 9.86 | -0.25 | -2.47% | 125.47M |
| VTROD | 1.30 | +0.00 | +0.00% |
